ISO 13485 Compliance: FDA Deadline 2026 | My ISO Consultants
Updated: Sep 18
The February 2, 2026 FDA deadline has now passed. The Quality Management System Regulation (QMSR) is in effect, and medical device manufacturers subject to 21 CFR Part 820 are now operating under the revised FDA quality-system framework.
The QMSR incorporates ISO 13485:2016 by reference and brings the FDA's medical device quality-system requirements into much closer alignment with the international standard. However, the change does not mean that the FDA requires manufacturers to obtain ISO 13485 certification, and an ISO 13485 certificate does not replace FDA compliance obligations or FDA inspections.
What the February 2, 2026 FDA Deadline Actually Meant
February 2, 2026 was the effective date of the FDA's Quality Management System Regulation. On that date, the revised 21 CFR Part 820 replaced the former Quality System Regulation framework and incorporated ISO 13485:2016 as the foundational quality management system standard for medical device manufacturers covered by the regulation.
The deadline was therefore not a requirement for every medical device company to become ISO 13485 certified by February 2, 2026. It was the date on which manufacturers subject to the FDA's QMSR were expected to comply with the new regulatory requirements.
ISO 13485 Certification and FDA QMSR Compliance Are Not the Same Thing
ISO 13485 certification is a third-party certification process. FDA QMSR compliance is a regulatory obligation. The two now share a closely aligned quality-management framework, but they are not interchangeable.
The FDA does not require an ISO 13485 certificate as a condition of QMSR compliance.
An ISO 13485 certificate does not exempt a manufacturer from FDA inspection.
FDA inspections assess compliance with FDA requirements, including the QMSR and other applicable provisions of the Federal Food, Drug, and Cosmetic Act and implementing regulations.
An organization can pursue ISO 13485 certification for customer, market, supply-chain, or international reasons while separately maintaining compliance with FDA requirements.
This distinction is important because the original transition discussion often used the terms ISO 13485 compliance, certification, and FDA compliance too loosely. Manufacturers should understand which obligations come from the FDA and which come from a certification or customer requirement.
What Changed Under the QMSR?
The QMSR does not simply rename the former Quality System Regulation. It incorporates ISO 13485:2016 by reference while retaining FDA-specific regulatory requirements that manufacturers must continue to address.
ISO 13485:2016 now provides the foundational quality-management-system framework within the QMSR.
Risk management has a more explicit role within the FDA quality-system framework.
The FDA may review management review, internal quality audit, and supplier audit records during inspections under the QMSR.
The former Quality System Inspection Technique, or QSIT, is no longer the FDA's inspection approach.
FDA device inspections now use the inspection process described in Compliance Program 7382.850.
Manufacturers must still meet applicable FDA requirements beyond ISO 13485 itself.
What Medical Device Manufacturers Should Focus on Now
Because the effective date has passed, the focus should no longer be on planning for a future transition. It should be on verifying that the current QMS is functioning under the QMSR and that objective evidence is available to demonstrate compliance.
Confirm that the current QMS has been evaluated against the QMSR and applicable FDA requirements.
Verify that procedures, records, and actual practices are aligned rather than relying on transition plans that were never fully implemented.
Review risk-management activities and how risk-based decisions are reflected in the QMS.
Make sure management review, internal audit, and supplier-audit records are inspection-ready where applicable.
Confirm that employees understand current procedures and responsibilities.
Address open gaps, recurring nonconformities, or ineffective corrective actions.
Prepare for the current FDA inspection process rather than relying on outdated QSIT terminology or inspection assumptions.
For a more detailed post-deadline verification checklist, see FDA QMSR Is Now in Effect: What Medical Device Manufacturers Need to Verify After February 2, 2026. That article is intended to cover the current compliance-verification stage in greater detail.
Does ISO 13485 Still Matter After the FDA Deadline?
Yes. ISO 13485:2016 remains the current published international standard for medical device quality management systems and was confirmed by ISO in 2025. Because the FDA has incorporated ISO 13485:2016 by reference into the QMSR, organizations operating in the U.S. medical device market now have even more reason to understand how their quality system aligns with the standard.
ISO 13485 can also remain important for customers, contract requirements, supplier qualification, international markets, and organizations pursuing independent certification. The business reason for certification should be evaluated separately from FDA regulatory compliance.
How ISO 13485 Consulting Support Can Help
A qualified consultant can help an organization separate certification requirements from FDA regulatory requirements, identify gaps in the current QMS, and focus effort on the controls and evidence that actually need attention.
QMSR and ISO 13485 gap analysis.
Review of existing procedures, records, and process implementation.
Risk-management and supplier-control review.
Internal audit and management-review readiness.
Corrective-action support.
ISO 13485 certification-readiness planning where certification is a business or customer objective.
Preparation for current FDA inspection expectations.
Organizations that need help evaluating their current system can use My ISO Consultants' ISO 13485 consulting services to identify gaps, strengthen implementation, and prepare for certification or regulatory readiness.
Frequently Asked Questions
Did the FDA require ISO 13485 certification by February 2, 2026?
No. February 2, 2026 was the effective date of the FDA's QMSR. The FDA incorporated ISO 13485:2016 by reference into the regulation, but it does not require manufacturers to obtain an ISO 13485 certificate in order to comply with the QMSR.
Does an ISO 13485 certificate prove FDA QMSR compliance?
No. ISO 13485 certification and FDA compliance are separate. Certification can demonstrate third-party conformity to ISO 13485, but the FDA still evaluates compliance with the QMSR and other applicable FDA requirements through its own regulatory oversight and inspection process.
Can the FDA review internal audit and management review records under the QMSR?
Yes. Under the QMSR, the FDA can review management review, quality audit, and supplier audit reports during inspections. The record-review exemptions that existed under the former Quality System Regulation are not maintained in the QMSR.
What should a company do if it missed the February 2, 2026 transition deadline?
The priority should be to assess the current QMS against the applicable QMSR requirements, identify unresolved gaps, document and implement necessary corrections, and verify that the system is working in practice. A structured gap analysis can help management prioritize the most significant compliance issues instead of attempting an unfocused rewrite of the entire QMS.
Conclusion
The February 2, 2026 FDA deadline is no longer an upcoming transition date. The QMSR is now the current FDA quality-system framework for medical device manufacturers subject to 21 CFR Part 820. The practical issue today is whether the organization's quality system is actually aligned with the QMSR, whether required controls are functioning, and whether objective evidence is ready for FDA review.
If your organization needs help determining where its medical device QMS stands today, My ISO Consultants provides ISO 13485 consulting services for gap analysis, QMS improvement, internal auditing, certification readiness, and current regulatory-alignment support.
